[Ip-health] Drug Regulation and Pricing — Can Regulators Influence Affordability?

Syed Ahmad drugsafetyconsultant at gmail.com
Wed May 11 16:49:01 PDT 2016


Dear All,

In an article published in the NEJM on May 12, authors from the European
Medicines Agency (EMA) et al., share their perspective on drug regulation
and high drug prices:

"*We firmly believe that assessment of quality, safety, and efficacy should
remain separate from pricing and reimbursement decisions. Regulators alone
cannot solve the growing problem of high drug prices*.”

Full article is available here: nejm.org/doi/full/10.10
56/NEJMp1601294#.VzPAaGBQzuM.twitter … <https://t.co/ZzthPelyfX>

Hope you will find this useful.

Rizwan

Syed Rizwanuddin Ahmad, MD, MPH, FISPE, FCP
Consultant with a Special Interest to Strengthen National
Medicines Regulatory Authorities in Resource-limited Countries
Ex-Consultant/Safety Reviewer, U.S. FDA (1998-2013)
Associate Professor (adjunct), Rutgers School of Public Health, NJ, USA
Assistant Professor (adjunct), Georgetown University School of Medicine,
Washington, DC, USA
www.drugsafetyconsultant.com



More information about the Ip-health mailing list